Budesonide for prevention of irinotecan (CPT-11)-induced diarrhea. Results of a double-blind, placebo-controlled, multicenter, randomized phase-III-study in patients with advanced colorectal cancer (CRC).

Karthaus, M., Ballo, H., Steinmetz, T., Geer, T., Schimke, J., Braumann, D., Behrens, R., Kindler, M., Greinwald, R., Kleeberg, U., 2003.